FDA 510(k)

HemoSphere Alta Advanced Monitoring Platform (ALTAALL1; ALTACR1; ALTASR1)

K-Number: K252533 · 2025-12-18

Decision Date2025-12-18

Product CodeDQK

Advisory CommitteeCV

DecisionSubstantially Equivalent

Device Summary

HemoSphere Alta Advanced Monitoring Platform (ALTAALL1; ALTACR1; ALTASR1) is the device name listed in this FDA 510(k) record. The listed applicant is Edwards Lifesciences. It received FDA 510(k) clearance on 2025-12-18 under 510(k) number K252533. The device is classified under product code DQK. It was reviewed by the CV advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the HemoSphere Alta Advanced Monitoring Platform (ALTAALL1; ALTACR1; ALTASR1)?

HemoSphere Alta Advanced Monitoring Platform (ALTAALL1; ALTACR1; ALTASR1) is a medical device that received FDA 510(k) clearance on 2025-12-18. The listed applicant is Edwards Lifesciences. The 510(k) number is K252533.

When did HemoSphere Alta Advanced Monitoring Platform (ALTAALL1; ALTACR1; ALTASR1) receive FDA 510(k) clearance?

HemoSphere Alta Advanced Monitoring Platform (ALTAALL1; ALTACR1; ALTASR1) received FDA 510(k) clearance on 2025-12-18, under 510(k) number K252533.

Who is the listed applicant for HemoSphere Alta Advanced Monitoring Platform (ALTAALL1; ALTACR1; ALTASR1)?

The FDA 510(k) record lists Edwards Lifesciences as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for HemoSphere Alta Advanced Monitoring Platform (ALTAALL1; ALTACR1; ALTASR1)?

The FDA product code for HemoSphere Alta Advanced Monitoring Platform (ALTAALL1; ALTACR1; ALTASR1) is DQK.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT02744677COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve DysfunctionRECRUITING NCT03230747SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral RegurgitationACTIVE_NOT_RECRUITING NCT03706833Edwards PASCAL CLASP IID/IIF Pivotal Clinical TrialACTIVE_NOT_RECRUITING NCT03745313Edwards CLASP TR EFSCOMPLETED NCT04097145Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical TrialRECRUITING NCT04375332Beating Heart Mitral Valve Repair With the HARPOON™ SystemACTIVE_NOT_RECRUITING

Other records listing Edwards Lifesciences as applicant

PMA P230013Percutaneously Delivered Prostheses and Tricuspid Valves PMA P860057replacement Heart-valve PMA P250019Prosthesis, mitral valve, percutaneously delivered PMA P220003Mitral valve repair devices PMA P200015Pulmonary valve prosthesis percutaneously delivered PMA P150048heart-valve, non-allograft tissue

View all 81 devices →

Related Devices (Code: DQK)

K253576CorVista System® with PCWP Add-OnAnalytics For Life, Inc.K262006EnSite™ X EP SystemAbbott Medical K252978ScioCardio ECG Analysis PlatformSynergen Technology Labs, LLC K253463ILR ECG Analyzer (IM007)Implicity, Inc.K261119NorthStar Mapping System (MAP01 or MAP01-01)Imricor Medical Systems, Inc.K253088OneStim-DUO Cardiac Stimulator (MP5003-4CO)Micropace Pty, Ltd.

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.